Advertisement

Osteoporosis International

, Volume 28, Issue 7, pp 2035–2044 | Cite as

Economic burden of osteoporosis-related hip fracture in Asia: a systematic review

  • N-A. Mohd-Tahir
  • S-C. LiEmail author
Review

Abstract

Summary

This review analyzes the economic costs of HF in Asia. The availability and quality of studies on the burden of osteoporosis in Asia are very scarce. There is a need to encourage more quality cost of osteoporosis studies based on standardized methods to convince healthcare authorities in implementing appropriate strategies.

Introduction

Osteoporosis fractures, especially hip fractures, impose large economic costs to governments and societies. This review aimed to systematically analyze available evidence on healthcare costs associated with osteoporosis-related hip fractures (HF) in Asia.

Methods

Articles were systematically sought from databases including PubMed, EMBASE, and EBSCOHost between 2000 and 2015. Total costs associated with HF care, the cost components, and length of stays were retrieved and analyzed. Study designs were also qualitatively analyzed.

Results

The availability of published studies on economic burden of HF in Asia is severely lacking with only 15 articles met the inclusion criteria. Even among the included studies, only two studies reported comprehensive costs evaluating all costs including indirect or intangible costs. Most studies satisfactorily reported criteria for conducting economic evaluation, but large variations existed in the methodological design. Due to study design and other influencing factors, large variation in the cost of HF treatment from US$774 to US$14,198.90 (median S$2943), representing an average of 18.95% (range: 3.58–57.05%) of the countries’ 2014 GDP/capita, was observed. This highlighted the heavy burden of managing HF in Asia with about 40% of the included studies reported using more than one third of GDP/capita.

Conclusion

There is a paucity of burden of illness studies of osteoporosis in the Asian region. For the few available studies, there was a lack of standardization in methodological approach in evaluating the economic burden of the disease. There is a need to encourage more quality burden of illness studies of osteoporosis to inform policymakers in healthcare planning.

Keywords

Burden of disease Cost of illnesses Fracture Healthcare costs Osteoporosis 

Notes

Compliance with ethical standards

Conflicts of interest

The views expressed in the submitted article are the authors own opinion’s and does not express the views of their official position of the institution or funder.

References

  1. 1.
    Mithal A, Kaur P (2012) Osteoporosis in Asia: a call to action. Current Osteoporosis Reports 10(4):245–247. doi: 10.1007/s11914-012-0114-3 CrossRefPubMedGoogle Scholar
  2. 2.
    Mithal A, Ebeling P, Kyer C (2013) The Asia-Pacific regional audit: epidemiology, costs, and burden of osteoporosis in 2013. International Osteoporosis FoundationGoogle Scholar
  3. 3.
    World Health Organization (2003) The burden of musculoskeletal conditions at the start of the new millennium: report of a WHO scientific group. World Health Organization, GenevaGoogle Scholar
  4. 4.
    Dhanwal DK, Dennison EM, Harvey NC, Cooper C (2011) Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop 45(1):15–22CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Mithal A, Dhingra V (2009) Epidemiology, costs and burden of osteoporosis in Asia 2009. The Asian Audit International Osteoporosis FoundationGoogle Scholar
  6. 6.
    Budhia S, Mikyas Y, Tang M, Badamgarav E (2012) Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. PharmacoEconomics 30(2):147–170. doi: 10.2165/11596880-000000000-00000 CrossRefPubMedGoogle Scholar
  7. 7.
    Drummond MF (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford University PressGoogle Scholar
  8. 8.
    Ben Sedrine W, Radican L, Reginster JY (2001) On conducting burden-of-osteoporosis studies: a review of the core concepts and practical issues. A study carried out under the auspices of a WHO collaborating center. Rheumatol (Oxf) 40(1):7–14CrossRefGoogle Scholar
  9. 9.
    The World Bank, World Development Indicators (2014) GDP per capita. Retrieved from http://databank.worldbank.org/data/. [database on the Internet]. Accessed: 13/10/2016
  10. 10.
    National Statistics Republic of China (Taiwan). Principal Figures 2014. Retrieved from http://eng.stat.gov.tw/ct.asp?xItem=37408&CtNode=5347&mp=5. [database on the Internet]. Accessed: 13/10/2016
  11. 11.
    Gao L, Hu H, Zhao F-L, Li S-C (2016) Can the direct medical cost of chronic disease be transferred across different countries? Using cost-of-illness studies on type 2 diabetes, epilepsy and schizophrenia as examples. PLoS One 11(1). doi: 10.1371/journal.pone.0147169
  12. 12.
    Zhao FL, Xie F, Hu H, Li SC (2013) Transferability of indirect cost of chronic disease: a systematic review and meta-analysis. PharmacoEconomics 31(6):501–508. doi: 10.1007/s40273-013-0053-6 CrossRefPubMedGoogle Scholar
  13. 13.
    Chan DC, Lee YS, Wu YJ, Tsou HH, Chen CT, Hwang JS et al (2013) A 12-year ecological study of hip fracture rates among older Taiwanese adults. Calcif Tissue Int 93(5):397–404CrossRefPubMedGoogle Scholar
  14. 14.
    Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H et al (2013) Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan. J Bone Miner Res 28(2):395–403CrossRefPubMedGoogle Scholar
  15. 15.
    Nagata-Kobayashi S, Shimbo T, Fukui T (2002) Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab (Eng ed) 20(6):350–357. doi: 10.1007/s007740200051 CrossRefGoogle Scholar
  16. 16.
    Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17(10):1459–1471. doi: 10.1007/s00198-006-0107-0 CrossRefPubMedGoogle Scholar
  17. 17.
    Ho WW, Kwan Dai DL, Liu KW, Chow KM, Lau E, Woo J et al (2009) To investigate the effect and cost-effectiveness of implementing an orthogeriatric intervention for elderly patients with acute hip fracture: the experience in Hong Kong. J Am Geriatr Soc 57(11):2153–2154. doi: 10.1111/j.1532-5415.2009.02529.x CrossRefPubMedGoogle Scholar
  18. 18.
    Shabat S, Heller E, Mann G, Gepstein R, Fredman B, Nyska M (2003) Economic consequences of operative delay for hip fractures in a non-profit institution. Orthopedics (Thorofare NJ) 26(12):1197–1199 discussion 9Google Scholar
  19. 19.
    Karn NK, Singh GK, Kumar P, Shrestha B, Singh MP, Gowda MJ (2006) Comparison between external fixation and sliding hip screw in the management of trochanteric fracture of the femur in Nepal. J Bone Jt Surg Br Vol 88(10):1347–1350. doi: 10.1302/0301-620x.88b10.18023 CrossRefGoogle Scholar
  20. 20.
    Borgstrom F, Lekander I, Ivergard M, Strom O, Svedbom A, Alekna V et al (2013) The international costs and utilities related to osteoporotic fractures study (ICUROS) - quality of life during the first 4 months after fracture. Osteoporos Int 24(3):811–823CrossRefPubMedGoogle Scholar
  21. 21.
    Sadat-Ali M, Al-Dakheel DA, Azam MQ, Al-Bluwi MT, Al-Farhan MF, AlAmer HA et al. (2015) Reassessment of osteoporosis-related femoral fractures and economic burden in Saudi Arabia. Arch Osteoporos. 10 (1) (no pagination)(37)Google Scholar
  22. 22.
    Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ (2015) Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int 26(7):1929–1937CrossRefPubMedGoogle Scholar
  23. 23.
    Segal E, Zinnman C, Raz B, Tamir A, Gurevich B, Siebzehner MI et al (2005) Second hip fracture in elderly hip fracture patients: cost and effectiveness of fracture prevention treatment. Age Ageing 34(5):507–510CrossRefPubMedGoogle Scholar
  24. 24.
    Xie Z, Burge R, Yang Y, Du F, Lu T, Huang Q et al. (2015) Posthospital discharge medical care costs and family burden associated with osteoporotic fracture patients in China from 2011 to 2013. J Osteoporos. 2015 (no pagination)(258089)Google Scholar
  25. 25.
    Qu B, Ma Y, Yan M, Wu HH, Fan L, Liao DF et al (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25(7):1853–1860. doi: 10.1007/s00198-014-2699-0 CrossRefPubMedGoogle Scholar
  26. 26.
    Saeb M, Beyranvand M, Basiri Z, Haghparast-Bidgoli H (2014) The hospital resource utilization associated with osteoporotic hip fractures in Kermanshah. Iran J Inj Violence Res 6(1):16–20PubMedGoogle Scholar
  27. 27.
    Kang HY, Park SE, Kang DR, Kim JY, Jang YH, Choi WJ et al (2009) Estimating medical expenditure associated with osteoporotic hip fracture in elderly Korean women based on the national health insurance claims database 2002-2004. Value Health 12(SUPPL. 3):S93–SS6CrossRefPubMedGoogle Scholar
  28. 28.
    Tanriover MD, Oz SG, Tanriover A, Kilicarslan A, Turkmen E, Guven GS et al (2010) Hip fractures in a developing country: osteoporosis frequency, predisposing factors and treatment costs. Arch Gerontol Geriatr 50(3):e13–ee8CrossRefPubMedGoogle Scholar
  29. 29.
    Lee YH, Lim YW, Lam KS (2008) Economic cost of osteoporotic hip fractures in Singapore. Singap Med J 49(12):980–984Google Scholar
  30. 30.
    Dai K, Zhang Q, Fan T, Sen SS (2007) Estimation of resource utilization associated with osteoporotic hip fracture and level of post-acute care in China. Curr Med Res Opin 23(12):2937–2943CrossRefPubMedGoogle Scholar
  31. 31.
    Chen LT, Lee JA, Chua BS, Howe TS (2007) Hip fractures in the elderly: the impact of comorbid illnesses on hospitalisation costs. Ann Acad Med Singap 36(9):784–787PubMedGoogle Scholar
  32. 32.
    Woratanarat P, Wajanavisit W, Lertbusayanukul C, Loahacharoensombat W, Ongphiphatanakul B (2005) Cost analysis of osteoporotic hip fractures. Chot Mai Het Thang Phaet 88(Suppl 5):S96–104PubMedGoogle Scholar
  33. 33.
    Ishizaki T, Imanaka Y, Oh E, Kuwabara K, Hirose M, Hayashida K et al (2004) Association of hospital resource use with comorbidity status and patient age among hip fracture patients in Japan. Health Policy (Amst Print) 69(2):179–187. doi: 10.1016/j.healthpol.2003.12.018 CrossRefGoogle Scholar
  34. 34.
    Hepguler S, Cetin A, Deger C, Erkent U (2011) Osteoporotic hip fracture costs in the elderly Turkish population. Acta Orthop Traumatol Turc 45(5):316–325PubMedGoogle Scholar
  35. 35.
    Bubshait D, Sadat-Ali M (2007) Economic implications of osteoporosis-related femoral fractures in Saudi Arabian society. Calcif Tissue Int 81(6):455–458CrossRefPubMedGoogle Scholar
  36. 36.
    Yang Y, Du F, Ye W, Chen Y, Li J, Zhang J et al (2015) Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis. ClinicoEcon Outcomes Res 7:205–212PubMedPubMedCentralGoogle Scholar
  37. 37.
    Dhar D (2006) The economic impact of treating geriatric hip fracture–a study at Rustag referral hospital, south batinah region. Oman Age and Ageing 3(3):17–19Google Scholar
  38. 38.
    Chang CY, Tang CH, Chen KC, Huang KC (2016) The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan. Osteoporos Int 27(2):665–676CrossRefPubMedGoogle Scholar
  39. 39.
    Kim J, Lee E, Kim S, Lee TJ (2016) Economic burden of osteoporotic fracture of the elderly in South Korea: a National Survey. Value in Health Regional Issues 9:36–41CrossRefPubMedGoogle Scholar
  40. 40.
    Liu GG, Eggleston K, Hu T-W (2008) Emerging health economics and outcomes research in the Asia-Pacific region. Value Health 11(Supplement 1(0)):S1–S2. doi: 10.1111/j.1524-4733.2008.00360.x CrossRefPubMedGoogle Scholar
  41. 41.
    Valzania C, Torbica A, Tarricone R, Leyva F, Boriani G (2016) Implant rates of cardiac implantable electrical devices in Europe: a systematic literature review. Health Policy (Amst Print) 120(1):1–15. doi: 10.1016/j.healthpol.2015.11.001 CrossRefGoogle Scholar
  42. 42.
    Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F et al (2009) Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12(4):409–418. doi: 10.1111/j.1524-4733.2008.00489.x CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Authors and Affiliations

  1. 1.Discipline of Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and PharmacyUniversity of NewcastleCallaghanAustralia
  2. 2.Faculty of PharmacyUniversiti Kebangsaan MalaysiaKuala LumpurMalaysia

Personalised recommendations